EverGlade Helps Sabin Vaccine Institute Secure up to $214 Million in BARDA Funding to Develop and Procure Ebola Sudan and Marburg Vaccines - EverGlade

EverGlade Helps Sabin Vaccine Institute Secure up to $214 Million in BARDA Funding to Develop and Procure Ebola Sudan and Marburg Vaccines

EverGlade has successfully secured up to $214 million in funding through a contract with BARDA to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

Featured In:
NY Daily News
US News
Time

AP
Chicago Tribune
The Denver Post
SF Gate

Everglade Helps Landmark Bio Secure Up To $18.3 Million in ARPA-H Funding

Everglade Helps Landmark Bio Secure Up To $18.3 Million in ARPA-H Funding

Read More
EverGlade blue logo cropped

Everglade Welcomes Dr. Patrick Sims, Expanding Its Technical and Federal Expertise

Read More
EverGlade

EverGlade Enters New Chapter of Growth: Welcomes Giacomo Apadula as Chief Executive Officer

Read More
Scroll to Top